UY30371A1 - Compuestos quimicos - Google Patents
Compuestos quimicosInfo
- Publication number
- UY30371A1 UY30371A1 UY30371A UY30371A UY30371A1 UY 30371 A1 UY30371 A1 UY 30371A1 UY 30371 A UY30371 A UY 30371A UY 30371 A UY30371 A UY 30371A UY 30371 A1 UY30371 A1 UY 30371A1
- Authority
- UY
- Uruguay
- Prior art keywords
- chemical compounds
- compounds
- formula
- cell cycle
- inhibitory activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describen compuestos de formula (I): que poseen actividad inhibitoria del ciclo celular.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80328306P | 2006-05-26 | 2006-05-26 | |
US86854006P | 2006-12-04 | 2006-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY30371A1 true UY30371A1 (es) | 2008-01-02 |
Family
ID=38449179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY30371A UY30371A1 (es) | 2006-05-26 | 2007-05-25 | Compuestos quimicos |
Country Status (8)
Country | Link |
---|---|
US (1) | US20090275567A1 (es) |
EP (1) | EP2032559A1 (es) |
JP (1) | JP2009538351A (es) |
AR (1) | AR061118A1 (es) |
CL (1) | CL2007001495A1 (es) |
TW (1) | TW200811169A (es) |
UY (1) | UY30371A1 (es) |
WO (1) | WO2007138268A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8178529B2 (en) | 2009-04-15 | 2012-05-15 | Astrazeneca Ab | Imidazole substituted pyrimidines |
JP5667913B2 (ja) * | 2011-03-15 | 2015-02-12 | 住友化学株式会社 | 2,3−ジクロロピリジンの製造方法 |
JP6399660B2 (ja) * | 2012-04-10 | 2018-10-03 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | 癌治療用組成物および方法 |
CN107987054B (zh) * | 2017-11-28 | 2020-05-19 | 四川大学 | 一种cdk2抑制剂 |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
WO2021030537A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
PE20221905A1 (es) | 2019-10-11 | 2022-12-23 | Incyte Corp | Aminas biciclicas como inhibidoras de la cdk2 |
TW202309030A (zh) | 2021-05-07 | 2023-03-01 | 美商凱麥拉醫療公司 | Cdk2降解劑及其用途 |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4659363A (en) * | 1983-07-25 | 1987-04-21 | Ciba-Geigy Corporation | N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof |
US4983608A (en) * | 1989-09-05 | 1991-01-08 | Hoechst-Roussell Pharmaceuticals, Inc. | N-substituted-4-pyrimidinamines and pyrimidinediamines |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
US5516775A (en) * | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
DE69329067T2 (de) * | 1992-10-05 | 2001-05-10 | Ube Industries, Ltd. | Pyridmidin-derivate |
US5739143A (en) * | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
JP3418624B2 (ja) * | 1996-06-10 | 2003-06-23 | メルク エンド カンパニー インコーポレーテッド | サイトカイン阻害活性を有する置換イミダゾール類 |
AU1507199A (en) * | 1997-12-15 | 1999-07-05 | Yamanouchi Pharmaceutical Co., Ltd. | Novel pyrimidine-5-carboxamide derivatives |
EA200000840A1 (ru) * | 1998-02-17 | 2001-02-26 | Туларик, Инк. | Антивирусные производные пиримидина |
AU5438299A (en) * | 1998-08-29 | 2000-03-21 | Astrazeneca Ab | Pyrimidine compounds |
DE69932828T2 (de) * | 1998-08-29 | 2007-10-18 | Astrazeneca Ab | Pyrimidine verbindungen |
GB9905075D0 (en) * | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB9907658D0 (en) * | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
GB9919778D0 (en) * | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
US7101869B2 (en) * | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
GB0004886D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004888D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0007371D0 (en) * | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
GB0021747D0 (en) * | 2000-09-04 | 2000-10-18 | Cambridge Consultants | Coating removal |
GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
GB0103926D0 (en) * | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
ATE416175T1 (de) * | 2001-02-20 | 2008-12-15 | Astrazeneca Ab | 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen |
SE0100569D0 (sv) * | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | New compounds |
WO2002096888A1 (de) * | 2001-05-29 | 2002-12-05 | Schering Aktiengesellschaft | Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel |
GB0113041D0 (en) * | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
EP1444223A1 (en) * | 2001-11-07 | 2004-08-11 | F. Hoffmann-La Roche Ag | Aminopyrimidines and -pyridines |
GB0205688D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
EP1490354A1 (en) * | 2002-03-09 | 2004-12-29 | Astrazeneca AB | 4-imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity |
GB0205693D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205690D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0311274D0 (en) * | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
GB0311276D0 (en) * | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
TW200528101A (en) * | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
EP1794134A1 (de) * | 2004-09-29 | 2007-06-13 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel |
AU2005295788A1 (en) * | 2004-10-13 | 2006-04-27 | Wyeth | N-benzenesulfonyl substituted anilino-pyrimidine analogs |
WO2006064251A1 (en) * | 2004-12-17 | 2006-06-22 | Astrazeneca Ab | 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors |
GB0504753D0 (en) * | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
AU2006274733B2 (en) * | 2005-07-30 | 2010-09-16 | Astrazeneca Ab | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders |
US7745428B2 (en) * | 2005-09-30 | 2010-06-29 | Astrazeneca Ab | Imidazo[1,2-A]pyridine having anti-cell-proliferation activity |
AR058073A1 (es) * | 2005-10-03 | 2008-01-23 | Astrazeneca Ab | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos |
JP2009510160A (ja) * | 2005-10-03 | 2009-03-12 | アストラゼネカ・アクチエボラーグ | アルツハイマー病を予防および/または治療するための医薬の製造におけるピリミジン誘導体の使用 |
EP2029578A1 (en) * | 2006-05-26 | 2009-03-04 | AstraZeneca AB | 2-carbocycloamino-4-imidaz0lylpyrimidines as agents for the inhbition of cell proliferation |
TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
TW200815417A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds II |
-
2007
- 2007-05-21 TW TW096117985A patent/TW200811169A/zh unknown
- 2007-05-23 AR ARP070102242A patent/AR061118A1/es not_active Application Discontinuation
- 2007-05-24 WO PCT/GB2007/001906 patent/WO2007138268A1/en active Application Filing
- 2007-05-24 CL CL2007001495A patent/CL2007001495A1/es unknown
- 2007-05-24 JP JP2009512656A patent/JP2009538351A/ja active Pending
- 2007-05-24 US US12/302,367 patent/US20090275567A1/en not_active Abandoned
- 2007-05-24 EP EP07732927A patent/EP2032559A1/en not_active Withdrawn
- 2007-05-25 UY UY30371A patent/UY30371A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP2032559A1 (en) | 2009-03-11 |
AR061118A1 (es) | 2008-08-06 |
JP2009538351A (ja) | 2009-11-05 |
CL2007001495A1 (es) | 2008-01-18 |
US20090275567A1 (en) | 2009-11-05 |
WO2007138268A1 (en) | 2007-12-06 |
TW200811169A (en) | 2008-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY30371A1 (es) | Compuestos quimicos | |
CY1119515T1 (el) | Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης | |
UY29612A1 (es) | Compuestos quimicos ii | |
EA201001359A1 (ru) | Гетероциклические соединения в качестве ингибиторов cxcr2 | |
CY1109911T1 (el) | Πυρρολοβενζοδιαζεπινες | |
TW200728290A (en) | Chemical compounds | |
NI200900151A (es) | Nuevo procedimiento de síntesis de la agomelatina. | |
UA107791C2 (en) | Pesticidal compositions | |
MY153915A (en) | Organic compounds | |
CO6491116A2 (es) | Derivados de 5-fluoropirimidinona | |
NI201000054A (es) | Compuestos químicos. | |
DK2134691T3 (da) | Quinolinonderivativer som parp- og tank-inhibitorer | |
TW200716543A (en) | Chemical compounds VII | |
GB0508318D0 (en) | Organic compounds | |
EA200901612A1 (ru) | Противовоспалительные соединения замещенных циклобутендионов | |
CR10960A (es) | Nuevo procedimiento de sintesis de la agomelatina | |
BR112012017277A2 (pt) | Compostos e métodos | |
CR20110381A (es) | Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2 | |
ATE417849T1 (de) | Pyrazoloä4,3-düpyrimidine | |
PA8797001A1 (es) | Nuevo procedimiento de sintesis del ranelato de estroncio y de sus hidratos | |
PA8792101A1 (es) | Nuevo procedimiento de sintesis del ( 7-metoxi-1- naftil) aceto | |
EA201270256A1 (ru) | Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида | |
TW200738686A (en) | Chemical compounds | |
EA200801366A1 (ru) | Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина | |
NI200900078A (es) | Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20170609 |